NEW YORK, Sept. 14 /PRNewswire-FirstCall/ -- Pfizer Inc said today that it has completed its acquisition of Vicuron Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato), a biopharmaceutical company focused on the development of novel anti-infectives for both hospital-based and community-acquired infections. In connection with the closing, shares of Vicuron common stock have been delisted from the Nasdaq and Italy's Nuovo Mercato stock exchanges effective today. Through the transaction, Pfizer has acquired two new product candidates currently under review at the U.S. Food and Drug Administration (FDA): anidulafungin for fungal infections and dalbavancin for Gram-positive infections. The addition of these product candidates broadens Pfizer's presence in anti-infectives where the company has a long history of providing patients and physicians with life-saving medicines. DATASOURCE: Pfizer Inc CONTACT: Paul Fitzhenry of Pfizer Inc, +1-212-733-4637 Web site: http://www.pfizer.com/ Company News On-Call: Pfizer's press releases are available through PR Newswire's Company News On-Call service on PRN's Web Site. Visit http://www.prnewswire.com/comp/688250.html Company News On-Call: http://www.prnewswire.com/comp/688250.html

Copyright